Aphase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

作者：Siegel, David S.^*; Martin, Thomas; Wang, Michael; Vij, Ravi; Jakubowiak, Andrzej J.; Lonial, Sagar; Trudel, Suzanne; Kukreti, Vishal; Bahlis, Nizar; Alsina, Melissa; Chanan-Khan, Asher; Buadi, Francis; Reu, Frederic J.; Somlo, George; Zonder, Jeffrey; Song, Kevin; Stewart, A. Keith; Stadtmauer, Edward; Kunkel, Lori; Wear, Sandra; Wong, Alvin F.; Orlowski, Robert Z.; Jagannath, Sundar

来源：Blood, 2012, 120(14): 2817-2825.

DOI：10.1182/blood-2012-05-425934

• PROTEASOME INHIBITOR CARFILZOMIB
• PERIPHERAL NEUROPATHY
• IRREVERSIBLE INHIBITOR
• DOSE DEXAMETHASONE
• CANCER STATISTICS
• RISK-FACTORS
• BORTEZOMIB
• UBIQUITIN
• COMBINATION
• TOXICITY

Carfilzomib is a next-generation, selective proteasome inhibitor being evaluated for the treatment of relapsed and refractory multiple myeloma. In this open-label, single-arm phase 2 study (PX-171-003-A1), patients received single-agent carfilzomib 20 mg/m(2) intravenously twice weekly for 3 of 4 weeks in cycle 1, then 27 mg/m(2) for <= 12 cycles. The primary endpoint was overall response rate (>= partial response). Secondary end-points included clinical benefit response rate (>= minimal response), duration of response, progression-free survival, overall survival, and safety. A total of 266 patients were evaluable for safety, 257 for efficacy; 95% were refractory to their last therapy; 80% were refractory or intolerant to both bortezomib and lenalidomide. Patients had median of 5 prior lines of therapy, including bortezomib, lenalidomide, and thalidomide. Overall response rate was 23.7% with median duration of response of 7.8 months. Median overall survival was 15.6 months. Adverse events (AEs) were manageable with-out cumulative toxicities. Common AEs were fatigue (49%), anemia (46%), nausea (45%), and thrombocytopenia (39%). Thirty-three patients (12.4%) experienced peripheral neuropathy, primarily grades 1 or 2. Thirty-three patients (12.4%) withdrew because of an AE. Durable responses and an acceptable tolerability profile in this heavily pretreated population demonstrate the potential of carfilzomib to offer meaningful clinical benefit. This trial was registered at www.clinicaltrials.gov as #NCT00511238. (Blood. 2012; 120(14): 2817-2825)

• 出版日期2012-10-4